Quantification of [11C]yohimbine binding to α2 adrenoceptors in rat brain in vivo

[1]  Yusuke Murayama,et al.  Tracing of noradrenergic projections using manganese-enhanced MRI , 2012, NeuroImage.

[2]  A. Landau,et al.  Amphetamine challenge decreases yohimbine binding to α2 adrenoceptors in Landrace pig brain , 2012, Psychopharmacology.

[3]  Alan A. Wilson,et al.  Isoflurane Anaesthesia Differentially Affects the Amphetamine Sensitivity of Agonist and Antagonist D2/D3 Positron Emission Tomography Radiotracers: Implications for In Vivo Imaging of Dopamine Release , 2011, Molecular Imaging and Biology.

[4]  Yun Zhou,et al.  Multi-graphical analysis of dynamic PET , 2010, NeuroImage.

[5]  Mark Slifstein,et al.  Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  Christina B. Castelino,et al.  Dopamine binds to α2-adrenergic receptors in the song control system of zebra finches (Taeniopygia guttata) , 2008, Journal of Chemical Neuroanatomy.

[7]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  S. Jakobsen,et al.  Detection of alpha-2 adrenergic receptors in brain of living pig with [11C]yohimbine , 2006, NeuroImage.

[9]  Donald F. Smith,et al.  Detection of α2-Adrenergic Receptors in Brain of Living Pig with 11C-Yohimbine , 2006 .

[10]  E. Peskind,et al.  Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer's Disease and Dementia with Lewy Bodies , 2006, The Journal of Neuroscience.

[11]  E. Robinson,et al.  Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002 , 2005, Synapse.

[12]  Douglas W. Smith,et al.  Human sympathetic activation by α2‐adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450–mediated drug metabolism , 2004, Clinical pharmacology and therapy.

[13]  H. Maurer,et al.  Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives , 2002, Therapeutic drug monitoring.

[14]  S. Tam,et al.  Yohimbine: a clinical review. , 2001, Pharmacology & therapeutics.

[15]  A. Matsuki,et al.  Increased noradrenaline release from rat preoptic area during and after sevoflurane and isoflurane anesthesia , 2001, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[16]  A. Gjedde,et al.  Basic CNS Drug Transport and Binding Kinetics In Vivo , 2000 .

[17]  David J. Begley,et al.  The Blood-brain Barrier and Drug Delivery to the CNS , 2000 .

[18]  M Rowland,et al.  Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[19]  H. Crawford,et al.  Tobacco affects P50 sensory gating: Auditory event-related potential differences in heavy tobacco smokers and nonsmokers , 2000, NeuroImage.

[20]  M. Millan,et al.  Agonist and antagonist actions of yohimbine as compared to fluparoxan at α2‐adrenergic receptors (AR)s, serotonin (5‐HT)1A, 5‐HT1B, 5‐HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states , 2000, Synapse.

[21]  V. Klimek,et al.  alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. , 1999, The Journal of pharmacology and experimental therapeutics.

[22]  J. Guimón,et al.  Up‐Regulation of Immunolabeled α2A‐Adrenoceptors, Gi Coupling Proteins, and Regulatory Receptor Kinases in the Prefrontal Cortex of Depressed Suicides , 1999, Journal of neurochemistry.

[23]  R. Wightman,et al.  Mechanisms of Amphetamine Action Revealed in Mice Lacking the Dopamine Transporter , 1998, The Journal of Neuroscience.

[24]  Hua Yang,et al.  The Binding of Cyclosporin A to Human Plasma: An in Vitro Microdialysis Study , 1996, Pharmaceutical Research.

[25]  J. S. Duncan,et al.  Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  N. Volkow,et al.  Effects of Blood Flow on [11C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET Data , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  S. Zoghbi,et al.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.

[28]  D. Bylund,et al.  Characterization of [3H]RX821002 binding to alpha-2 adrenergic receptor subtypes. , 1994, The Journal of pharmacology and experimental therapeutics.

[29]  G. Ordway,et al.  Characterization of subtypes of alpha-2 adrenoceptors in the human brain. , 1993, The Journal of pharmacology and experimental therapeutics.

[30]  P. Watkins.  The role of cytochromes P-450 in cyclosporine metabolism. , 1990, Journal of the American Academy of Dermatology.

[31]  A. Gjedde,et al.  Blood—Brain Transfer and Metabolism of 6-[18F]Fluoro-L-DOPA in Rat , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  D. Bylund.  Sub types of α2-adrenoceptors: Pharmacological and molecular biological evidence converg , 1988 .

[34]  J. Gustafsson,et al.  Regional Distribution of Cytochrome P‐450 in the Rat Brain: Spectral Quantitation and Contribution of P‐450b,e and P‐450c,d , 1988, Journal of neurochemistry.

[35]  F. Leslie,et al.  Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[36]  S. Loughlin,et al.  Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[37]  J. Schwartz,et al.  Characteristics of the [3H]-yohimbine binding on rat brain α2 , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

[38]  R. Wurtman,et al.  Decrease in neostriatal blood flow after d-amphetamine administration or electrical stimulation of the substantia nigra , 1977, Brain Research.

[39]  B. K. Hartman,et al.  Central noradrenergic regulation of cerebral blood flow and vascular permeability. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Gregory F Ball,et al.  Dopamine binds to alpha(2)-adrenergic receptors in the song control system of zebra finches (Taeniopygia guttata). , 2008, Journal of chemical neuroanatomy.

[41]  D. Bylund,et al.  Platelet alpha 2-adrenergic receptor binding and the effects of d-amphetamine in boys with attention deficit hyperactivity disorder. , 1994, Neuropsychobiology.

[42]  U. Schambra,et al.  Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. , 1994, Brain research. Molecular brain research.

[43]  U. Schambra,et al.  Distribution of α2-adrenergic receptor subtype gene expression in rat brain , 1994 .

[44]  D. Bylund,et al.  Platelet alpha2-adrenergic receptor binding and the effects of d-amphetamine in boys with attention deficit hyperactivity disorder , 1994 .

[45]  D. Bylund.  Subtypes of alpha 2-adrenoceptors: pharmacological and molecular biological evidence converge. , 1988, Trends in pharmacological sciences.

[46]  M. Schlossberg.  PET and NMR: New Perspectives in Neuroimaging and in Clinical Neurochemistry. , 1987 .

[47]  F. Gerstenbrand,et al.  PET and NMR : new perspectives in neuroimaging and in clinical neurochemistry : proceedings of a symposium held in Padova, Italy, May 15-17, 1985 , 1986 .